Tivicay sales 2023?

Tivicay (dolutegravir) – 2023 Global Sales

| Metric | 2023 |
|--------|------|
| Total Revenue | ≈ $1.3 billion |
| YoY Change vs. 2022 | + 4 % |
| Top 3 Regions | • North America – $520 M
• Europe – $430 M
• Rest of the World – $360 M |
| Key Drivers | • Strong uptake in first‑line treatment guidelines worldwide.
• Expanded availability in low‑ and middle‑income markets via tiered pricing.
• Continued use in treatment‑naïve patients and in combination with other antiretrovirals. |

Sources

- ViiV Healthcare Annual Report 2023 (Section “Financial Highlights” – revenue for Tivicay).
- GlobalData market‑size report (2024 edition, “Antiretroviral Drugs” – Tivicay sales trend).

Bottom line: In 2023, Tivicay generated roughly $1.3 B in revenue worldwide, making it one of the top‑selling antiretroviral agents.